Zobrazeno 1 - 10
of 16
pro vyhledávání: '"D. E. Milenic"'
Autor:
Karen J. Wong, J Lee, William D. Figg, D. E. Milenic, Yolanda Y. McKinney, Stephen Adler, Esther Mena, Shivaani Kummar, P. L. Choyke, S Lipkowitz, Baris Turkbey, Maria Merino, Liza Lindenberg, James H. Doroshow, C H Paik, Tristan M. Sissung, Karen A. Kurdziel, Martin W. Brechbiel
Publikováno v:
Journal of translational science
Introduction Tumors over-expressing the human epithelial receptor 2 (HER2) or exhibiting amplification or mutation of its proto-oncogene have a poorer prognosis. Using trastuzumab and/or other HER2 targeted therapies can increase overall survival in
Autor:
K. Garmestani, D. E. Milenic, M. W. Brechbiel, Celeste A. S. Regino, P. L. Choyke, Karen J. Wong, E. H. Holmes
Better tumor markers are needed for early diagnosis and staging of prostate cancer, and for monitoring therapeutic response than the currently used prostate specific antigen (PSA). Prostate specific membrane antigen (PSMA) is highly expressed on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33cacbab70aa3bc35dfcbb35a91805e9
https://europepmc.org/articles/PMC2678849/
https://europepmc.org/articles/PMC2678849/
Autor:
D J, Buchsbaum, B E, Rogers, M B, Khazaeli, M S, Mayo, D E, Milenic, S V, Kashmiri, C J, Anderson, L L, Chappell, M W, Brechbiel, D T, Curiel
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5
Novel strategies to increase the therapeutic ratio in clinical radioimmunotherapy studies are needed. Limitations to radioimmunotherapy include bone marrow suppression due to the long circulating half-life of radiolabeled monoclonal antibodies (mAbs)
Publikováno v:
Cancer gene therapy. 4(4)
While in vivo gene inoculation is being increasingly exploited to express genes of choice and elicit specific immune responses in animal models, the utility of this method has not been explored extensively for the expression of antibody genes. The pr
Autor:
D C, Slavin-Chiorini, S V, Kashmiri, J, Schlom, B, Calvo, L M, Shu, M E, Schott, D E, Milenic, P, Snoy, J, Carrasquillo, K, Anderson
Publikováno v:
Cancer research. 55
CC49 is a second-generation monoclonal antibody (MAb) that has high affinity for the tumor-associated pancarcinoma antigen tumor-associated glycoprotein-72. In clinical trials using gamma scanning, radiolabeled CC49 has facilitated the detection of m
Autor:
T, Mulligan, J A, Carrasquillo, Y, Chung, D E, Milenic, J, Schlom, I, Feuerstein, C, Paik, P, Perentesis, J, Reynolds, G, Curt
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 1(12)
CC49, a murine monoclonal antibody that recognizes the tumor-associated glycoprotein 72, was conjugated to the chemical chelate 1,4,7,10-tetraaza-1-(1-carboxy-3-(4-aminophenyl) propyl)-tris-4,7,10- ((carboxy)methyl)cyclododecane that had been labeled
Publikováno v:
Cancer research. 55(13)
Previous studies have shown that (a) single-chain antibody binding proteins, or sFvs, localize experimental tumor xenografts (D.E. Milenic et al, Cancer Res., 51: 6363-6371, 1991) and (b) the administration of gamma-interferon (IFN-gamma) increases t
Autor:
M, Roselli, C L, Hitchcock, A, Molinolo, D E, Milenic, D, Colcher, E W, Martin, G H, Hinkle, J, Schlom
Publikováno v:
Anticancer research. 15(3)
Monoclonal antibody B72.3 recognizes a pancarcinoma antigen termed TAG-72 and is the MAb in "OncoScint CR/OV". Patients undergoing surgical resection of primary or metastatic colorectal or breast carcinoma or pseudomyxoma peritonei were injected i.v.
Autor:
M E, Schott, J, Schlom, K, Siler, D E, Milenic, D, Eggensperger, D, Colcher, R, Cheng, W J, Kruper, W, Fordyce, W, Goeckeler
Publikováno v:
Cancer. 73
Lutetium-177 (177Lu), samarium-153 (153Sm), and yttrium-90 (90Y) are members of the family of elements known as lanthanides or rare earths. Monoclonal antibody CC49, a murine immunoglobulin (Ig) G1, which is reactive with the tumor-associated antigen
Publikováno v:
Cancer research. 53(16)
In previous studies, we have compared the immunochemical properties, the in vivo pharmacokinetics, and the tumor penetrance of a radioiodinated single-chain Fv (sFv) in comparison with other immunoglobulin (Ig) forms (intact IgG, F(ab')2, and Fab') (